serena williams glp-1 commercial faces backlash after Super Bowl Ad promoting weight-loss drug 📄 Inside Serena Williams’ partnership

Potential limitations include: Limited long-term human data Variable patient response Cost considerations Need for ongoing monitoring Off-label prescribing considerations These therapies are generally avoided in patients with: Active malignancy Pregnancy or breastfeeding Significant uncontrolled endocrine disease Certain metabolic conditions Monitoring and Safety Where prescribed, monitoring may include: IGF-1 levels Functional recovery Sleep quality Rehabilitation tolerance Adverse effects Overall clinical progress Treatment should always be part of a broader recovery plan rather than a standalone intervention

First-line conservative approaches include patient education, avoiding exacerbating wrist movements, wearing wrist splints, physical therapy (PT), exercise, and local corticosteroid injections (CSIs)

Most people regain weight and lose metabolic benefits after stopping

This fat is then stored in the liver, where it builds up and can eventually lead to metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD)